EP 3592730 B1 20210804 - PRODRUGS OF SULFASALAZINE, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE IN THE TREATMENT OF AUTOIMMUNE DISEASE
Title (en)
PRODRUGS OF SULFASALAZINE, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE IN THE TREATMENT OF AUTOIMMUNE DISEASE
Title (de)
PRODRUGS VON SULFASALAZIN, PHARMAZEUTISCHE ZUSAMMENSETZUNGEN DAVON UND DEREN VERWENDUNG IN DER BEHANDLUNG VON AUTOIMMUNKRANKHEITEN
Title (fr)
PROMÉDICAMENTS DE SULFASALAZINE, COMPOSITIONS PHARMACEUTIQUES DE CEUX-CI ET LEUR UTILISATION DANS LE TRAITEMENT D'UNE MALADIE AUTO-IMMUNE
Publication
Application
Priority
- SE 1750262 A 20170309
- EP 2018055720 W 20180308
Abstract (en)
[origin: WO2018162625A1] The present invention relates to new compounds of formula (I) and pharmaceutically acceptable salts and/or co-crystals thereof. The present invention also relates to pharmaceutical compositions comprising these compounds and to their use as medicaments for the prevention, prophylaxis of progression, and/or treatment of a disease in which modulation of extracellular (chemotactic) cytokines and/or TNF-alpha and or nuclear factor kappa B (NFKB) and/or inflammatory cells is beneficial, such as autoimmune diseases, like rheumatoid arthritis, oligoarthritis, spondyloarthropathy, psoriatic arthritis, psoriasis and inflammatory bowel diseases, such as Crohns' disease and ulcerative colitis.
IPC 8 full level
C07D 213/76 (2006.01); A61K 31/4402 (2006.01); A61P 37/00 (2006.01)
CPC (source: EP US)
A61P 37/00 (2017.12 - EP); C07D 213/76 (2013.01 - EP US)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
DOCDB simple family (publication)
WO 2018162625 A1 20180913; EP 3592730 A1 20200115; EP 3592730 B1 20210804; US 10703723 B2 20200707; US 2020017446 A1 20200116
DOCDB simple family (application)
EP 2018055720 W 20180308; EP 18711058 A 20180308; US 201816491317 A 20180308